A5055362101- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Lung Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Treatments and Mutations
- Meningioma and schwannoma management
- Lung Cancer Research Studies
- Advanced Radiotherapy Techniques
- Medical Imaging Techniques and Applications
- Cancer Genomics and Diagnostics
- Neurofibromatosis and Schwannoma Cases
- Vascular Malformations Diagnosis and Treatment
- Palliative Care and End-of-Life Issues
- Patient-Provider Communication in Healthcare
- Cancer-related cognitive impairment studies
- Histone Deacetylase Inhibitors Research
- Pituitary Gland Disorders and Treatments
- Childhood Cancer Survivors' Quality of Life
- Epigenetics and DNA Methylation
- Cancer survivorship and care
- PARP inhibition in cancer therapy
- Cancer, Hypoxia, and Metabolism
- Health Systems, Economic Evaluations, Quality of Life
- Neuroendocrine Tumor Research Advances
- Management of metastatic bone disease
University of Edinburgh
2011-2024
Western General Hospital
2015-2024
Edinburgh Cancer Research
2012-2024
University of Liverpool
2021-2022
Walton Centre
2022
NHS Lothian
2015-2021
Dana-Farber Cancer Institute
2017
Wellcome Trust
2014
RTOG Foundation
2013
Medical Research Council
2010
Purpose Radiotherapy with concomitant and adjuvant temozolomide is the standard of care for newly diagnosed glioblastoma (GBM). O 6 -methylguanine-DNA methyltransferase (MGMT) methylation status may be an important determinant treatment response. Dose-dense (DD) results in prolonged depletion MGMT blood mononuclear cells possibly tumor. This trial tested whether DD improves overall survival (OS) or progression-free (PFS) patients GBM. Patients Methods phase III enrolled older than age 18...
Temozolomide (TMZ) is an alkylating agent licensed for treatment of high-grade glioma (HGG). No prospective comparison with nitrosourea-based chemotherapy exists. We report, to our knowledge, the first randomized trial procarbazine, lomustine, and vincristine (PCV) versus TMZ in chemotherapy-naive patients recurrent HGG.Four hundred forty-seven were randomly assigned PCV (224 patients) or (sub-random assignment: TMZ-5 [200 mg/m(2) 5 days, 112 patients] TMZ-21 [100 21 111 patients]) up 9...
Although descriptive classifications of meningioma subtypes are well established, there has been inconsistency in the categorization meningiomas into benign, atypical and anaplastic groups. The aim this study was to reassess incidence (grade II) over a 10‐year period by applying World Health Organization (WHO) 2000 classification system. A secondary determine if grade II III tumours were becoming more common. Sections 314 resected between 1994 2003 retrieved from archives Western General...
Radiation with concurrent and adjuvant (6 cycles) temozolomide (TMZ) is the established standard of postsurgical care for newly diagnosed glioblastoma (GBM). This regimen has been adopted variations, including extending TMZ beyond 6 cycles. The optimal duration maintenance therapy remains controversial. We performed pooled analysis individual patient data from 4 randomized trials GBM. All patients who were progression free 28 days after cycle included. decision to continue was per local...
The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib potentiated radiation and temozolomide (TMZ) chemotherapy in preclinical glioblastoma models but brain penetration was poor. Clinically, PARP inhibitors exacerbate the hematological side effects of TMZ. OPARATIC trial conducted to measure recurrent by assess safety tolerability its combination with
Abstract Purpose: In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas molecular features glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase–wildtype (IDH-wt) 2021 World Health Organization (WHO) classification central nervous system tumors]. Patients and Methods: From randomized phase III study examining addition adjuvant concurrent...
Quantitative studies show people living with a lower-grade glioma (LGG) often report low health-related quality of life. However, it is unclear how this impact experienced; resulting supportive care needs are also poorly understood. We explored experience the long-term an LGG, to help identify potential needs. conducted semi-structured interviews diverse group LGG (n = 28) across United Kingdom, who had completed primary treatment (male n 16, female 12, mean age 54.6 years, time since...
BackgroundThe ESTRO Health Economics in Radiation Oncology (HERO) project has the overall aim to develop a knowledge base of provision radiotherapy Europe and build model for health economic evaluation radiation treatments at European level. The first milestone was assess availability resources within Europe. This paper presents personnel data collected HERO database.Materials methodsAn 84-item questionnaire sent out countries, through their national scientific professional societies....
Abstract Background No systemic treatment has been established for meningioma progressing after local therapies. Methods This randomized, multicenter, open-label, phase II study included adult patients with recurrent WHO grade 2 or 3 meningioma. Patients were 2:1 randomly assigned to intravenous trabectedin (1.5 mg/m2 every weeks) standard of care (LOC). The primary endpoint was progression-free survival (PFS). Secondary endpoints comprised overall (OS), objective radiological response,...
Survival in patients with IDH1/2-mutant (mt) anaplastic astrocytomas is highly variable. We have used the prospective phase 3 CATNON trial to identify molecular factors related outcome IDH1/2mt astrocytoma patients.The randomized 751 adult newly diagnosed 1p/19q non-codeleted glioma 59.4 Gy radiotherapy +/- concurrent and/or adjuvant temozolomide. The presence of necrosis microvascular proliferation was scored at central pathology review. Infinium MethylationEPIC BeadChip arrays were for...
Abstract Somatic mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 occur at high frequency several tumour types. Even though these are confined to distinct hotspots, we show that gliomas only type with an exceptionally percentage of R132H mutations. Patients harbouring mutated tumours have lower levels genome-wide DNA-methylation, associated increased gene expression, compared other IDH1/2 (“non-R132H mutations”). This reduced methylation is seen multiple types thus appears...
Abstract Objective To understand factors influencing the process of adjustment to a diagnosis glioma. Methods Twenty‐six patients and 23 relatives took part in 80 in‐depth qualitative interviews conducted at five key stages: before formal diagnosis, start treatment, on completion 6 months post bereavement. Results High levels distress were reported, particularly preceding following diagnosis. Many participants described lack specific information early their illness clarity about what was...
2000 Background: The 1st interim analysis of the CATNON trial showed benefit from adjuvant (adj) temozolomide (TMZ) on overall survival (OS) but remained inconclusive about concurrent (conc) TMZ. A 2 nd was planned after 356 events. Methods: 2x2 factorial design phase III randomized 751 adult patients with newly diagnosed non-codeleted anaplastic glioma to either 59.4 Gy radiotherapy (RT) alone; same RT concTMZ; and 12 cycles adjTMZ or both concTMZ ( doi: 10.1016/S0140-6736(17)31442-3). MGMT...
LBA2009 Background: Cilengitide (CIL) is a selective αvβ3 and αvβ5 integrin inhibitor. In phase II study in patients with newly diagnosed glioblastoma, CIL added to standard temozolomide (TMZ) radiotherapy (RT) was well tolerated appeared confer improved survival glioblastoma methylated MGMT gene promoter (Stupp et al. J Clin Oncol. 2010;28:2712-8). Methods: This multicenter, randomized, controlled, open-label, III randomized (1:1) (≥ 18 years) diagnosed, histologically proven supratentorial...
<h3>Objective:</h3> To evaluate the prevalence of mental incapacity to make neuro-oncologic treatment decisions and identify patients likely experience difficulty with medical decision-making enable a more rigorous focused assessment. <h3>Methods:</h3> The preoperative capacity give valid consent neurosurgery 100 radiologically suspected intracranial tumors was assessed. Mental formally assessed using MacArthur Competence Assessment Tool for Treatment (MACCAT-T) conducted by dual-qualified...